KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Inventory (2016 - 2026)

Biogen has reported Inventory over the past 18 years, most recently at $1.9 billion for Q1 2026.

  • For Q1 2026, Inventory fell 14.29% year-over-year to $1.9 billion; the TTM value through Mar 2026 reached $1.9 billion, down 14.29%, while the annual FY2025 figure was $2.2 billion, 11.88% down from the prior year.
  • Inventory for Q1 2026 was $1.9 billion at Biogen, down from $2.2 billion in the prior quarter.
  • Over five years, Inventory peaked at $3.0 billion in Q3 2023 and troughed at $1.2 billion in Q1 2022.
  • A 5-year average of $2.0 billion and a median of $2.2 billion in 2025 define the central range for Inventory.
  • Biggest five-year swings in Inventory: surged 116.9% in 2023 and later fell 17.21% in 2024.
  • Year by year, Inventory stood at $1.3 billion in 2022, then surged by 87.99% to $2.5 billion in 2023, then dropped by 2.65% to $2.5 billion in 2024, then decreased by 11.88% to $2.2 billion in 2025, then decreased by 10.11% to $1.9 billion in 2026.
  • Business Quant data shows Inventory for BIIB at $1.9 billion in Q1 2026, $2.2 billion in Q4 2025, and $2.2 billion in Q3 2025.